• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    enGene Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    6/10/25 5:26:39 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENGN alert in real time by email
    false000198084500019808452025-06-102025-06-100001980845us-gaap:CommonClassAMember2025-06-102025-06-100001980845engn:CommonSharesMember2025-06-102025-06-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 10, 2025

    enGene Holdings Inc.
    (Exact name of registrant as specified in its charter)


    British Columbia
     
    001-41854
     
    00-0000000
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)

    4868 Rue Levy, Suite 220
    Saint-Laurent, Quebec
     
    H4R 2P1
    (Address of principal executive offices)
     
    (Zip code)

    Registrant's telephone number, including area code (514) 332-4888

    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Shares
    ENGN
    NASDAQ
    Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Common Share
    ENGNW
    NASDAQ

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒


    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    Approval of the enGene Holdings Inc. 2025 Employee Stock Purchase Plan
    As described in Item 5.07 of this Current Report on Form 8-K, on June 10, 2025, at its 2025 Annual General Meeting of shareholders (the “Annual Meeting”), the shareholders of enGene Holdings Inc. (the “Company”) approved the adoption of the 2025 Employee Stock Purchase Plan  (the “ESPP”), pursuant to which 2,000,000 common shares of the Company, no par value (the “Common Shares”), will be reserved for issuance.
    The ESPP is intended to promote the interests of the Company by providing eligible employees with the opportunity to acquire a proprietary interest in the Company through participation in an employee stock purchase plan designed to qualify under Section 423 of the Internal Revenue Code of 1986 (the “Code”) for one or more specified offerings made under the Plan, or where determined appropriate by the Plan Administrator under Section 3(b), outside the requirements of Code Section 423. The number of Common Shares reserved for issuance under the ESPP will be limited to 2,000,000 shares. The shares issuable under the ESPP will be made available from authorized but unissued common shares. Shares that are cancelled, terminated, forfeited, fail to vest, or for any other reason are not paid or delivered under the ESPP will generally be available for subsequent offering periods under the ESPP. The Plan is effective as of June 10, 2025, which was the date of the Annual Meeting.
    For a further description of the terms and conditions of the ESPP, as approved by shareholders, see “Proposal 2: Approval of the 2025 Employee Stock Purchase Plan Proposal” in the Company’s definitive Proxy Statement, as filed with the Securities and Exchange Commission on May 9, 2025 (the “Proxy Statement”), which description is incorporated herein by reference.
    The foregoing description of the ESPP, including the description contained in the Proxy Statement, is qualified in its entirety by reference to the full text of the ESPP, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
    Item 5.07. Submission of Matters to a Vote of Security Holders.
    The Annual Meeting of the Company was held on June 10, 2025 at 8:30 a.m. EDT. A total of 38,101,263 of the Company’s  Common Shares were present or represented by proxy at the Annual Meeting, representing approximately 74.60% of the Company’s 51,070,851 Common Shares that were outstanding and entitled to vote at the Annual Meeting as of the record date of April 29, 2025.
    Set forth below, and pursuant to the requirements set out in subsection 11.3 of National Instrument 51-102, are the final voting results for each of the matters submitted to a vote of the shareholders at the Annual Meeting, which matters are each described in further detail in the Company’s Proxy Statement:
    Proposal 1 – Election of Directors


                 
    Director Nominee
     
    For
     
    Withhold
     
    Broker Non-Votes
    Gerald Brunk
     
    30,481,847
     
    8,154
     
    7,611,262
    Dr. Richard Glickman
     
    26,312,872
     
    4,177,129
     
    7,611,262

    Proposal 2 – Approval of the enGene Holdings Inc. 2025 Employee Stock Purchase Plan


                 
    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
    30,152,713
     
    8,427
     
    328,861
     
    7,611,262
    Proposal 3 – Appointment and Remuneration of Auditor


    For
     
    Withhold
     
    Broker Non-Votes
    38,101,229
     
    34
     
    -

    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits
     
         
    Exhibit Number
      
    Description
       
    10.1
      
    enGene Holdings Inc. 2025 Employee Stock Purchase Plan
       
    104
      
    Cover Page Interactive Data File (Formatted as Inline XBRL)


    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


     
    ENGENE HOLDINGS INC.
     
     
    Date: June 10, 2025
    By:
     /s/ Ronald H. W. Cooper
     
    Name: Ronald H. W. Cooper
     
    Title: Chief Executive Officer


    Get the next $ENGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENGN

    DatePrice TargetRatingAnalyst
    2/18/2025$26.00Overweight
    Piper Sandler
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    12/23/2024$25.00Buy
    H.C. Wainwright
    11/27/2024$23.00Outperform
    Raymond James
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    8/28/2024$30.00Outperform
    Oppenheimer
    4/22/2024$30.00Overweight
    Wells Fargo
    4/15/2024$34.00Buy
    Guggenheim
    More analyst ratings

    $ENGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Zoth Lota S.

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      6/16/25 6:40:38 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Global Comm. Ofc. Pott Amy

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      6/16/25 6:40:07 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Joustra Wouter

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      6/16/25 6:39:30 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care